Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,ELISA 1:40000,Not yet tested in other applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Haltbarkeit
12 months
Target
BCAP31
(B-Cell Receptor-Associated Protein 31 (BCAP31))
Andere Bezeichnung
BAP31
Hintergrund
BCAP31, BAP31, DXS1357E, B-cell receptor-associated protein 31, BCR-associated protein 31, Bap31, 6C6-AG tumor-associated antigen, Protein CDM, p28BCAP31 encodes a member of the B-cell receptor associated protein 31 superfamily. The encoded protein (B-cell receptor-associated protein 31) is a multi-pass transmembrane protein of the endoplasmic reticulum that is involved in the anterograde transport of membrane proteins from the endoplasmic reticulum to the Golgi and in caspase 8-mediated apoptosis. Microdeletions in this gene are associated with contiguous ABCD1/DXS1375E deletion syndrome (CADDS), a neonatal disorder. Alternative splicing of BCAP31 results in multiple transcript variants. Two related pseudogenes have been identified on chromosome 16.